Vimian enters specialised veterinary soft tissue surgery with Norfolk acquisition

12/11/2026

The proposed deal adds a US implant and consumables specialist to Vimian MedTech, extending the group’s reach into procedures associated with long-term and chronic animal care.

Vimian’s proposed acquisition of Norfolk Medical Products gives the Stockholm-based animal-health group a new position in specialised veterinary soft tissue surgery, a clinical niche built around implantable solutions and associated consumables for long-term or chronic interventions.

The transaction is modest in headline size but strategically specific. Norfolk generated around USD 6.9 million in revenue in the 12 months to August 2026, according to Vimian’s 21 October announcement. The family-owned Chicago business, founded in 1981, supplies veterinary-specific products including vascular access ports and solutions used in urinary, pulmonary and fluid-management procedures.

Norfolk manufactures at its own facility and sells directly to veterinary clinics in the United States, while using distributors across Europe and Asia-Pacific. That combination of production, clinical distribution and specialist education gives Vimian an operating platform beyond a conventional product catalogue. Training and education developed with leading specialists are a core part of Norfolk’s model.

Norfolk is due to join Vimian’s MedTech segment. The company has identified cross-selling and faster veterinary education as potential benefits, while Norfolk’s existing relationships could provide a route for the group’s wider surgical offer into specialist settings. The commercial opportunity will depend on how successfully those channels are integrated; Vimian has not disclosed a purchase price or a revenue forecast for the acquired business.

The deal arrives as Vimian reports continued growth across its four segments: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. In its third-quarter results, published the day after the Norfolk announcement, the group reported revenue of EUR 120.3 million, up 15 per cent year on year, including 11 per cent organic growth. Adjusted EBITA rose 14 per cent to EUR 29.2 million, with a 24.3 per cent margin.

The 21 October release stated that the acquisition would be financed with available funds and expected to have only a marginal effect on 2026 earnings per share. It also put expected completion on or around 2 November, but did not include a subsequent closing notice. The significance therefore lies less in a near-term earnings contribution than in adding a specialised procedural category with repeat-use consumables, clinical training and international distribution potential.

For further information > Vimian